Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Over the last decade intense efforts have been
2021-09-07

Over the last decade, intense efforts have been devoted toward identifying IN inhibitors as potential drugs against HIV. Raltegravir and elvitegravir are integrase strand transfer inhibitors (INSTIs) that have been approved for therapy and dolutegravir is another INSTI that is currently in advanced
-
br Materials and methods br Results br Discussion I
2021-09-07

Materials and methods Results Discussion I have identified an alternative transcript of the integrin αE gene that is abundantly expressed in testis. In humans, this transcript (hAED) includes part of intron 26 and exons 27, 29, 30, and 31 of the conventional αE gene and Northern analysis in
-
Several classes of small molecules that modulate CDK activit
2021-09-07

Several classes of small molecules that modulate CDK8 activity have been reported in the patent literature (Fig. 1). A quinazoline derivative, Senexin B (SNX2-1–165, 1), showed CDK8 enzyme inhibitory activity with an IC50 value of 24–50 nM in different assay, and displayed potent, selective enzymati
-
br Introduction In the treatment of
2021-09-07

Introduction In the treatment of patients with AIDS and human immunodeficiency virus type 1 (HIV-1), anti-retroviral therapy (ART), which uses anti-HIV drugs such as protease inhibitors, integrase inhibitors and reverse transferase inhibitors, has made a major contribution. There are still some s
-
br Material and methods br Results
2021-09-07

Material and methods Results Discussion Organisms have developed a variety of anti-glycation defense mechanisms. In TCS PIM-1 1 to the aldose-reductase-pathway or 2-oxoaldehyde dehydrogenase-pathway, the glyoxalase system is the only mechanism, which is not restricted to liver [19]. This sy
-
The life cycle of T cruzi requires both vertebrate and
2021-09-07

The life cycle of T. cruzi requires both vertebrate and invertebrate hosts. In the insect (invertebrate) vector, the protozoan undergoes extracellular replication, whereas in the mammalian (vertebrate) host it replicates by obligate intracellular multiplication (Rodrigues et al., 2014). Hence, the p
-
In the present study co administration of TM AT
2021-09-07

In the present study, co-administration of TM (AT1 receptor blocker) and PD (AT2 receptor blocker) were made in ischemic mice to explore the significance of AT2 receptors in cerebral ischemia while blocking central AT1 receptors. Also to prove that AT2 receptors should be free after ischemic injury
-
Studies of human and mouse GPR as
2021-09-07

Studies of human and mouse GPR84, as ascertained by mRNA levels in various tissues, have determined that GPR84 is highly expressed on bone marrow cells, splenic T and B cells, and circulating granulocytes/monocytes/macrophages. In the latter cells, mRNA expression of is up-regulated only under infla
-
Long non coding RNAs lncRNAs are mRNA like transcripts of
2021-09-07

Long non-coding RNAs (lncRNAs) are mRNA-like transcripts of greater than 200 nucleotides (nt), with little or no protein-coding potential [13,14]. LncRNAs have been suggested to participate in transcription and post-transcription regulation as scaffolds, guides, decoys or repressors, activators, and
-
dpp-4 br Acknowledgements This study was supported by
2021-09-06

Acknowledgements This study was supported by National Institutes of Health grant (R01GM104037), VA grant (BX002741), and Rutgers Busch grant. Nuclear receptor FXR is the master regulator of bile acids homeostasis The farnesoid X receptor (FXR) belongs to a family of proteins known as nuclear
-
Lenvatinib is an orally available multi targeted
2021-09-06

Lenvatinib is an orally available, multi-targeted tyrosine kinase inhibitor against VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT [11,12]. In a recent phase III trial for patients with previously untreated uHCC (REFLECT study), lenvatinib showed statistical non-inferiority of overall survival compared to
-
br Molecular mechanisms and pathways for ferroptosis
2021-09-06

Molecular mechanisms and pathways for ferroptosis regulation As to the regulation of lipid peroxidation, iron and related ROS metabolism involved in ferroptosis, many molecular mechanisms and pathways have been presented. It is generally believed that cystine/glutamate antiporter system Xc−, GPX4
-
It has been suggested that MAPK Huang et al
2021-09-06

It has been suggested that MAPK (Huang et al., 2013, Uddman et al., 2003, Xu et al., 2008) signaling pathway is involved in the transcriptional upregulation of ETB receptor. The present study demonstrated that treatment with CsA increased phosphorylation of ERK1/2 and p38. Inhibition of ERK1/2 and p
-
A second H R antagonist with benzamide based
2021-09-06

A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass
-
Based on our results we propose three possible mechanisms
2021-09-06

Based on our results, we propose three possible mechanisms of HER2 loss after trastuzumab-based therapy (Fig. 3). The first possibility is a result of the differential effects of treatments on clonal subsets. In breast cancer, such selective pressure has been suggested to preferentially eradicate HE
14801 records 581/987 page Previous Next First page 上5页 581582583584585 下5页 Last page